drugset

drugset / Trial / NCT02996838

A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

NCT02996838 ↗

Phase 1 Unknown 20 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To study the pharmacokinetic characteristics of TQ-B3234 in the human body, recommend a reasonable regimen for subsequent research.

Timeline

Start: 2017-05-11
Primary completion: 2020-12
Completion: 2020-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQ-B3234	Unknown	—	Oral

Indications